Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Oct 24:17:774-781.
doi: 10.12659/ajcr.899754.

High-Dose Intravenous Vitamin C Treatment of a Child with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Case Report

Nina Mikirova  1 , Ronald Hunnunghake  2 , Ruth C Scimeca  1 , Charles Chinshaw  3 , Faryal Ali  3 , Chris Brannon  2 , Neil Riordan  4
Affiliations
Case Reports

High-Dose Intravenous Vitamin C Treatment of a Child with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Case Report

Nina Mikirova et al. Am J Case Rep. .

Abstract

BACKGROUND In neurofibromatosis type 1 (NF1) disease, the loss of the tumor suppressor function of the neurofibromin gene leads to proliferation of neural tumors. In children, the most frequently identified tumor is the optic pathway glioma. CASE REPORT We describe the case of a 5-year-old child who was diagnosed with NF1 and optic pathway tumor onset at the age of 14 months. Because of the tumor progression, chemotherapy with carboplatin and vincristine was prescribed at this early age and continued for one year. As the progression of disease continued after chemotherapy, the child, at the age of 2.8 years, was started on high-dose intravenous vitamin C (IVC) treatment (7-15 grams per week) for 30 months. After 30 months, the results of IVC treatments demonstrated reduction and stabilization of the tumors in the optic chiasm, hypothalamus, and left optic nerve according to radiographic imaging. The right-sided optic nerve mass seen before IVC treatment disappeared by the end of the treatment. CONCLUSIONS This case highlights the positive effects of treating NF1 glioma with IVC. Additional studies are necessary to evaluate the role of high-dose IVC in glioma treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared

Figures

Figure 1.
Figure 1.
The changes of the abnormal T2 bright foci within the bilateral cerebellum and decrease of the left optic portion of the optic pathway tumor during chemotherapy treatment.
Figure 2.
Figure 2.
Treatment schedule of the patient.
Figure 3.
Figure 3.
Changes of the hypothalamic/optic chiasm tumor during chemotherapy and IVC treatments.
Figure 4.
Figure 4.
Magnetic resonance images before (A) and after (B) IVC treatment. Circled areas show the optic chiasm and hypothalamic region.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Listernick R, Charrow J. Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet. 1999;89:38–44. - PubMed
    1. Friedman JM, Gutmann DH, MacCollin M, et al. Neurofibromatosis: Phenotype, natural history and pathogenesis. 3rd ed. John Hopkins University Press; Baltimore: 1999.
    1. Listernick R, Charrow J, Greenwald MJ, et al. Optic gliomas in children with neurofibromatosis type 1. J Pediatr. 1989;114:788–92. - PubMed
    1. Listernick R, Louis DN, Packer RJ, et al. Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the NF1 Optic pathway glioma Task Force. Ann Neurol. 1997;41:143–49. - PubMed
    1. King A, Listernick R, Charrow J, et al. Optic pathway gliomas in neurofibromatosis type 1: The effect of presenting symptoms on outcome. Am J Med Genet A. 2003;10:1002. - PubMed

Publication types

MeSH terms